StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
19
This year
1
Publishing Date
2024 - 03 - 05
1
2023 - 10 - 25
1
2023 - 09 - 13
1
2023 - 09 - 07
1
2023 - 07 - 17
1
2023 - 04 - 26
2
2022 - 09 - 08
1
2022 - 08 - 29
1
2022 - 08 - 03
1
2022 - 06 - 09
1
2022 - 01 - 21
1
2021 - 11 - 05
1
2021 - 10 - 27
1
2021 - 10 - 18
1
2021 - 08 - 05
1
2021 - 05 - 03
1
2021 - 04 - 19
1
2021 - 01 - 07
1
Sector
Health technology
19
Tags
Alliances
1
Alzheimer’s
4
Biocanada
1
Blood
1
Cardiovascular
1
Care
1
Clinical-trials-phase-i
1
Clinical-trials-phase-ii
1
Clinical-trials-phase-iii
5
Disease
4
Drug
1
Fda
1
Genetown
8
Hepatitis
1
Hypertension
1
Meeting
1
Nephropathy
2
Pharmaceutical
1
Phase 2
2
Phase 3
6
Positive
19
Positive results
2
Report
2
Research
1
Results
13
Risk
1
Study
5
Technology
1
Topline
7
Treat
1
Treatment
5
Trial
1
Entities
Abbvie inc.
32
Adial pharmaceuticals, inc
10
Alnylam pharmaceuticals, inc.
19
Amgen inc.
17
Annovis bio, inc.
10
Aquestive therapeutics, inc.
18
Arrival
33
Astellas pharma inc
16
Astrazeneca plc
18
Beigene, ltd.
21
Beyondspring, inc.
11
Biogen inc.
13
Biontech se
18
Bridgebio pharma, inc.
16
Bristol-myers squibb company
33
Celldex therapeutics, inc.
10
Clearside biomedical, inc.
15
Coherus biosciences, inc.
24
Dare bioscience, inc.
13
Eli lilly and company
34
Fortress biotech, inc.
10
Gartner, inc.
31
Gilead sciences, inc.
14
Glaxosmithkline plc
13
Hoth therapeutics, inc.
14
I-mab
10
Immix biopharma, inc.
11
Immutep limited
13
In8bio inc
10
Incyte corporation
17
Ionis pharmaceuticals, inc.
21
Johnson & johnson
55
Kering
13
Lithium corp
18
Mediwound ltd.
11
Merck & company, inc.
21
Morgan stanley
12
Myovant sciences ltd.
10
Nasdaq, inc.
87
Novartis ag
25
Orange
40
Parsons corporation
14
Pds biotechnology corporation
12
Pfizer, inc.
46
Pliant therapeutics, inc.
10
Regeneron pharmaceuticals, inc.
26
Regenxbio inc.
17
Rocket pharmaceuticals, inc.
11
Sanofi
114
Scynexis, inc.
11
Seagen inc.
13
Sellas life sciences group, inc.
11
Sorrento therapeutics, inc.
22
Takeda pharmaceutical company limited
15
Taylor devices, inc.
17
Teva pharmaceutical industries ltd
14
Tonix pharmaceuticals holding corp.
12
Vertex pharmaceuticals incorporated
11
Viracta therapeutics inc
14
Zai lab limited
11
Symbols
ALNY
19
LLY
1
NVO
1
REGN
4
SNY
13
SNYNF
12
Exchanges
Nasdaq
19
Nyse
1
Crawled Date
2024 - 03 - 05
1
2023 - 10 - 25
1
2023 - 09 - 13
1
2023 - 09 - 07
1
2023 - 07 - 17
1
2023 - 04 - 26
2
2022 - 09 - 08
1
2022 - 08 - 29
1
2022 - 08 - 03
1
2022 - 06 - 09
1
2022 - 01 - 21
1
2021 - 11 - 05
1
2021 - 10 - 27
1
2021 - 10 - 18
1
2021 - 08 - 05
1
2021 - 05 - 03
1
2021 - 04 - 19
1
2021 - 01 - 07
1
Crawled Time
08:00
1
09:00
1
12:00
3
13:00
2
14:30
1
15:00
1
16:00
1
18:00
1
19:00
2
21:00
2
22:00
2
23:00
2
Source
www.biospace.com
19
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
positive
entities :
Alnylam pharmaceuticals, inc.
save search
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published:
2024-03-05
(Crawled : 16:00)
- biospace.com/
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
0.13%
|
O:
1.17%
H:
0.0%
C:
0.0%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-2.65%
|
O:
-0.73%
H:
1.52%
C:
0.5%
positive
blood
care
topline
results
study
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-10-25
(Crawled : 19:00)
- biospace.com/
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-8.94%
|
O:
0.4%
H:
1.29%
C:
1.29%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-10.17%
|
O:
1.43%
H:
0.64%
C:
-0.09%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-10.91%
|
O:
-1.28%
H:
0.58%
C:
-1.46%
disease
alzheimer’s
positive
results
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-09-13
(Crawled : 22:00)
- biospace.com/
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-13.88%
|
O:
-1.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-14.08%
|
O:
-0.99%
H:
0.0%
C:
0.0%
fda
positive
treatment
meeting
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
Published:
2023-09-07
(Crawled : 14:30)
- biospace.com/
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-10.67%
|
O:
1.03%
H:
0.0%
C:
0.0%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-27.49%
|
O:
-0.15%
H:
1.32%
C:
-0.02%
positive
treat
risk
topline
hypertension
cardiovascular
results
study
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-07-17
(Crawled : 09:00)
- biospace.com/
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-10.72%
|
O:
0.02%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
26.28%
|
O:
0.05%
H:
1.33%
C:
0.38%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-25.89%
|
O:
5.53%
H:
5.23%
C:
-2.49%
disease
alzheimer’s
positive
results
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-04-26
(Crawled : 23:00)
- biospace.com/
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-16.59%
|
O:
-1.46%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-18.13%
|
O:
0.53%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
14.91%
|
O:
-0.99%
H:
0.38%
C:
-0.48%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-27.74%
|
O:
-0.76%
H:
0.33%
C:
-1.54%
disease
report
alzheimer’s
positive
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-04-26
(Crawled : 23:00)
- biospace.com/
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-16.59%
|
O:
-1.46%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-18.13%
|
O:
0.53%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
14.91%
|
O:
-0.99%
H:
0.38%
C:
-0.48%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-27.74%
|
O:
-0.76%
H:
0.33%
C:
-1.54%
disease
report
alzheimer’s
positive
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published:
2022-09-08
(Crawled : 08:00)
- biospace.com/
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
22.79%
|
O:
-0.65%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
17.56%
|
O:
-0.47%
H:
0.0%
C:
0.0%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-30.06%
|
O:
-1.67%
H:
10.61%
C:
10.19%
positive
results
study
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published:
2022-08-29
(Crawled : 13:00)
- biospace.com/
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
13.37%
|
O:
-1.08%
H:
0.0%
C:
0.0%
REGN
|
News
|
$906.55
-0.09%
-0.08%
370K
|
Health Technology
|
52.19%
|
O:
-0.64%
H:
1.24%
C:
0.07%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-30.75%
|
O:
-0.56%
H:
1.41%
C:
-0.34%
treatment
nephropathy
positive
study
phase 2
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published:
2022-08-03
(Crawled : 12:00)
- biospace.com/
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-6.49%
|
O:
-2.6%
H:
0.0%
C:
-0.76%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-5.05%
|
O:
-0.17%
H:
0.12%
C:
-1.29%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
2.89%
|
O:
47.44%
H:
0.0%
C:
0.0%
topline
positive
results
study
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published:
2022-06-09
(Crawled : 12:00)
- biospace.com/
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-11.47%
|
O:
-0.88%
H:
0.0%
C:
0.0%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
7.22%
|
O:
1.59%
H:
0.68%
C:
-2.46%
treatment
nephropathy
topline
positive
phase 2
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published:
2022-01-21
(Crawled : 13:00)
- biospace.com/
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
0.03%
|
O:
-10.41%
H:
0.0%
C:
0.0%
positive
results
phase 3
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Published:
2021-11-05
(Crawled : 22:00)
- biospace.com/
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-8.18%
|
O:
0.0%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-9.48%
|
O:
-1.65%
H:
0.0%
C:
0.0%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-21.28%
|
O:
-0.02%
H:
0.0%
C:
0.0%
positive results
positive
results
phase 3
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published:
2021-10-27
(Crawled : 21:00)
- biospace.com/
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-26.34%
|
O:
-0.42%
H:
0.24%
C:
-3.2%
positive
results
topline
phase 3
Alnylam Receives Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) for use of GIVLAARI for the Treatment of Acute Hepatic Porphyria (AHP) in Adults
Published:
2021-10-18
(Crawled : 18:00)
- biospace.com/
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-29.96%
|
O:
0.14%
H:
0.0%
C:
-2.37%
treatment
positive
drug
technology
hepatitis
Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
Published:
2021-08-05
(Crawled : 21:00)
- biospace.com/
NVO
|
News
|
$126.16
-1.93%
-0.23%
3.1M
|
Health Technology
|
30.98%
|
O:
3.16%
H:
1.88%
C:
1.77%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
181.58%
|
O:
0.31%
H:
0.85%
C:
0.35%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-20.37%
|
O:
0.2%
H:
5.7%
C:
5.5%
treatment
positive
results
trial
topline
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
Published:
2021-05-03
(Crawled : 12:00)
- biospace.com/
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-10.14%
|
O:
-4.18%
H:
1.62%
C:
1.41%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
3.86%
|
O:
-0.11%
H:
0.09%
C:
-3.66%
positive
results
phase 3
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
Published:
2021-04-19
(Crawled : 19:00)
- biospace.com/
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
5.18%
|
O:
-0.39%
H:
1.79%
C:
-0.68%
positive results
positive
results
phase 3
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published:
2021-01-07
(Crawled : 15:00)
- biospace.com/
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
15.17%
|
O:
5.35%
H:
4.77%
C:
4.33%
positive
results
phase 3
topline
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.